Policy Supported
Letters Supported & Letters Submitted
Patients Rising Now’s Comments on Oregon’s 1115 Waiver and Impact on Access
The FDA’s Accelerated Approval Program provides a path for earlier approval of drugs being developed to treat serious diseases and address unmet medical need. The process allows the use of a surrogate endpoint—an indirect marker of clinical benefit that allows the...
Letter in support of the nomination of Dr. Robert Califf to serve as Commissioner of the Food and Drug Administration
On behalf of Patients Rising, the organization representing millions of Americans living with chronic disease, I write to support the nomination of Dr. Robert Califf to serve as Commissioner of the Food and Drug Administration. The U.S. Food and Drug Administration...
Letter Supported: Importance of Orphan Drug Tax Credit for People and Families Living with Autoimmune Disease
On behalf of the estimated 50 million Americans with autoimmune and immune-mediated diseases, the undersigned 64 organizations write to you regarding the importance of the Orphan Drug Tax Credit (ODTC) for people and families living with autoimmune disease and urge...
Letter Supported: Step Therapy for Part B Drugs in Medicare Advantage
The undersigned organizations, representing millions of Medicare beneficiaries with life-threatening, complex, chronic conditions and/or the physicians who care for them, are asking the Centers for Medicare and Medicaid Services (CMS) to ensure that beneficiaries...
Letter Supporting S.4111 Breslin/A.4668 Peoples-Stokes Prohibiting Non-medical Switching
This year S.4111 Breslin/A.4668 Peoples-Stokes overwhelmingly passed both the New York State Senate and Assembly with bipartisan support; a loud and unified message underscoring the importance of putting patients first. Once signed into law, this bill will prohibit...
Patient Community Concerns with Drug Pricing Proposals
We, the undersigned 46 organizations, on behalf of millions of American patients who live with complex, chronic health conditions such as HIV, autoimmune diseases, cancer, diabetes, lupus, multiple sclerosis, and hepatitis, are pleased that your committee and Congress...
Ban Co-pay Accumulator Programs in Massachusetts
Show your support for S. 644 and H.1053 which would ban co-pay accumulator programs in Massachusetts. Many Insurers and PBMs are now utilizing copay accumulators to stop copay assistance from counting towards a patient’s deductible and maximum out-of-pocket spending....
Cigna’s Letters to Patients and Providers on Cosentyx
Patient groups, advocates, and providers have seen disturbing media reports about Cigna’s recent letter to patients and providers regarding the use of Cosentyx. In the letter, patients are encouraged to switch to a Cigna-preferred drug, as Cosentyx was removed from...
An ACT RELATING TO INSURANCE – PRESCRIPTION DRUG BENEFITS
We, the undersigned, want to express our support for S0859, a much-needed bill that will protect patient access to co-pay assistance programs many Rhode Islanders depend on to cover significant portions of prescription medicine co-pays. We thank you for co-sponsoring...
International Reference Pricing and Alzheimer’s Disease
The undersigned organizations are writing, in anticipation of the reintroduction of the Elijah E. Cummings Lower Drug Costs Now Act (i.e., H.R. 3), to urge Congress to keep any international reference pricing proposals (including "International Pricing Index" or...
Cigna’s Recent Letter to Patients and Providers Regarding the Use of Cosentyx
Patient groups, advocates, and providers have seen disturbing media reports about Cigna’s recent letter to patients and providers regarding the use of Cosentyx. In the letter, patients are encouraged to switch to a Cigna-preferred drug, as Cosentyx was removed from...
Patient and Provider Group Rebate Wall Sign On Letter
On behalf of the undersigned organizations representing diverse patient and provider stakeholders who are concerned with the effects of rebate walls on patient treatment access, we greatly appreciate your leadership on critical efforts to protect patient well-being....